Evidence map›Paper›PMID 39499485›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations.

Guillermo Suay, Paloma Martín-Martorell, Francisco Aparisi, María Arnal, María Guirado, Aitor Azkárate, Javier Garde-Noguera, José David Cumplido-Burón, Amelia Insa, José Francisco González-Muñoz and 4 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Molecular epidemiology and outcomes ofTranslational lung cancer research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Guillermo SuayMedical Oncology Department, Biomarker and Precision Medicine Unit, La Fe University and Polytechnic Hospital, Valencia, Spain.
Paloma Martín-MartorellMedical Oncology Department, University Clinical Hospital, Valencia, Spain.
Francisco AparisiMedical Oncology Investigator, Biomarker and Precision Medicine Unit, Health Research Institute Hospital La Fe, Valencia, Spain.
María ArnalMedical Oncology Department, Provincial Hospital Consortium, Castellón, Spain.
María GuiradoMedical Oncology Department, General University Hospital of Elche, Alicante, Spain.
Aitor AzkárateMedical Oncology Department, Son Espases University Hospital, Palma, Spain.
Javier Garde-NogueraMedical Oncology Department, Arnau de Vilanova Hospital, Valencia, Spain.
José David Cumplido-BurónMedical Oncology Department, Torrevieja University Hospital, Alicante, Spain.
Amelia InsaMedical Oncology Department, University Clinical Hospital, Valencia, Spain.
José Francisco González-MuñozDepartment of Pathology, Biomedical Research Institute INCLIVA, Valencia, Spain.
Sarai PalancaClinical Analysis Department, Molecular Biology Unit, La Fe University and Polytechnic Hospital, Valencia, Spain.
María DíazClinical Analysis Department, Castellón University General Hospital, Castellón de La Plana, Spain.
Alfredo Sánchez-HernándezMedical Oncology Department, Provincial Hospital Consortium, Castellón, Spain.
Óscar Juan-VidalMedical Oncology Department, Biomarker and Precision Medicine Unit, La Fe University and Polytechnic Hospital, Valencia, Spain. juan_osc@gva.es.ORCID http://orcid.org/0000-0002-7772-9030

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesEGFR exon 20 insertion (EGFRex20ins) mutations are found in up to 4% of all patients with non-small cell lung cancer (NSCLC). These patients are often insensitive to EGFR-tyrosine kinase inhibitors (TKIs) and have worse prognosis than patients with more common EGFR mutations. In this multicenter, retrospective, real-world study, we sought to determine whether the administration of recently approved treatments that specifically target EGFRex20ins mutations could significantly improve outcomes in this patient population. MATERIALS AND

methodsWe evaluated the clinical features of 41 patients diagnosed with NSCLC and EGFRex20ins mutations, their evolution, and response to treatments received across 7 hospitals in the Valencian Community, Spain, between 31st December 2012 and 31st December 2022.

results32 patients (72%) developed metastatic disease, and 29 (71%) of them received oncological treatment. We found that administering a targeted therapy against EGFRex20ins mutations (amivantamab, mobocertinib and/or sunvozertinib) at some point during the course of treatment, significantly increased the median OS of metastatic patients from 8 months (95% CI 0-21.7) to 30 months (95% CI 11.1-48.8; Hazard ratio = 0.297, p = 0.02).

conclusionOur findings contribute to the evolving standard of care for this specific population and highlight the clinical benefits of targeted cancer therapies.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutagenesis, InsertionalAdultAgedAged, 80 and overErbB ReceptorsExonsFemaleHumansMaleMiddle AgedMutationPrognosisProtein Kinase InhibitorsRetrospective StudiesEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsEGFR exon 20 insertion mutationsNon-small cell lung cancerOverall survivalReal-world dataTargeted therapies

Identifiers

PMID39499485

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.